Role of Antifungal Susceptibility Testing in Non-Aspergillus Invasive Mold Infections.

Published

Journal Article

No clinical breakpoints are available to delineate antifungal drug efficacy in non-Aspergillus invasive mold infections (NAIMIs). In this analysis of 39 NAIMI episodes, the MIC of the first-line antifungal drug was the most important predictor of therapeutic response. For amphotericin B, an MIC of ≤0.5 μg/ml was significantly associated with better 6-week outcomes.

Full Text

Duke Authors

Cited Authors

  • Lamoth, F; Damonti, L; Alexander, BD

Published Date

  • June 2016

Published In

Volume / Issue

  • 54 / 6

Start / End Page

  • 1638 - 1640

PubMed ID

  • 27008871

Pubmed Central ID

  • 27008871

Electronic International Standard Serial Number (EISSN)

  • 1098-660X

Digital Object Identifier (DOI)

  • 10.1128/JCM.00318-16

Language

  • eng

Conference Location

  • United States